References
- Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus–report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56(10):1515–1523.
- Sutter R, Kaplan PW. Can anesthetic treatment worsen outcome in status epilepticus? Epilepsy Behav. 2015;49:294–297.
- Logroscino G, Hesdorffer DC, Cascino G, et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia. 2005;46(Suppl 11):46–48.
- Falco-Walter JJ, Bleck T. Treatment of established status epilepticus. J Clin Med. 2016;5(5):49.
- Dorandeu F, Dhote F, Barbier L, et al. Treatment of status epilepticus with ketamine, are we there yet? CNS Neurosci Ther. 2013;19(6):411–427.
- Hocker S, Tatum WO, LaRoche S, et al. Refractory and super-refractory status epilepticus–an update. Curr Neurol Neurosci Rep. 2014;14(6):452.
- Ferlisi M, Hocker S, Grade M, et al. International Steering Committee of the StEp Audit. Preliminary results of the global audit of treatment of refractory status epilepticus. Epilepsy Behav. 2015;49:318–324.
- Beg JM, Anderson TD, Francis K, et al. Burden of illness for super-refractory status epilepticus patients. J Med Econ. 2017;20(1):45–53.
- De Kock M, Loix S, Lavand’homme P. Ketamine and peripheral inflammation. CNS Neurosci Ther. 2013;19(6):403–410.
- Dorandeu F, Barbier L, Dhote F, et al. Ketamine combinations for the field treatment of soman-induced self-sustaining status epilepticus. Review of current data and perspectives. Chem Biol Interact. 2013;203(1):154–159.
- Barbier L, Canini F, Giroud C, et al. Beneficial effects of a ketamine/atropine combination in soman-poisoned rats under a neutral thermal environment. Neurotoxicology. 2015;50:10–19.
- Zeiler FA, West M. Ketamine for status epilepticus: Canadian physician views and time to push forward. Can J Neurol Sci. 2015;42(2):132–134.
- Chang LC, Raty SR, Ortiz J, et al. The emerging use of ketamine for anesthesia and sedation in traumatic brain injuries. CNS Neurosci Ther. 2013;19(6):390–395.
- Fang Y, Wang X. Ketamine for the treatment of refractory status epilepticus. Seizure. 2015;30:14–20.
- Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498–1503.
- Basha MM, Alqallaf A, Shah AK. Drug-induced EEG pattern predicts effectiveness of ketamine in treating refractory status epilepticus. Epilepsia. 2015;56(4):e44-8.
- Hofler J, Rohracher A, Kalss G, et al. (S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study. CNS Drugs. 2016;30(9):869–876.
- Zeiler FA. Early use of the NMDA receptor antagonist ketamine in refractory and superrefractory status epilepticus. Crit Care Res Pract. 2015;2015:831260.
- Ilvento L, Rosati A, Marini C, et al. Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation. Epilepsy Behav. 2015;49:343–346.
- Rosati A, Ilvento L, L’Erario M, et al. Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01). BMJ Open. 2016;6(6):e011565.